Patient and doctor


We focus on developing therapies against targets where existing preclinical and early clinical data is available. This data can give a strong indication that a therapy will disrupt a targeted biochemical process and improve patient outcome without significant side-effects. Sareum’s approach is lower risk than developing therapies against entirely novel targets.

We currently have one development programme (Chk1) in two Phase 2 clinical trials, being conducted by licence partner Sierra Oncology, with a further two trials planned. The other development programme (Aurora+FLT3) is in preclinical development.

Development Programmes Jun16

Click here for our latest research update

  • @Sareumplc Latest tweet

    Roche's discontinuation of its CHK1 inhibitor, RG7741 (aka Genentech's GDC-0575), means this mechanism is now a two… via @Sareumplc
    View more